Gamida Cell

Indonesia
Sumbul, North Sumatra, Indonesia, 95464

Company profile

Gamida Cell company profile

Gamida Cell is a biopharmaceutical company developing advanced cell therapies for patients with blood cancers and hematologic diseases. Its product includes NiCord, a cell therapy based on NAM-expanded cord blood developed to improve and extend the life-saving benefits of hematopoietic stem cell transplant. The company applies an expansion platform supporting the properties of NAM to allogeneic cell sources that include omidubicel, an investigational product with potential as a life-saving alternative for patients in need of bone marrow transplant.

Business identity

Contact email
[email protected]
Phone number
97226595616
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Revenue range
$0-$1M
Founded
1998-01-01, Year

Headquarters

Postal code
95464
Country code
ID
Continent
Asia

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
13
Total equity funding
$184.9M
Last funding
Post IPO Debt / $25M / 2022-09-28
Last equity funding
Post IPO Equity / $60M
Investors
14
Lead investors
5
Founders
1
Articles
170
Exited on
2018-10-25

Founders and investors

Founders

Tony Peled

Lead investors

Auriga PartnersHighbridge Capital ManagementIsrael Healthcare VenturesIsrael Innovation AuthorityShavit Capital

Investors

Israel Biotech FundIsrael Innovation AuthorityNovartisTeva PharmaceuticalsVMS Asset Management